您搜索了: sabrina (挪威语 - 英语)

sabrina bryan
byou

studie bo22334 (sabrina)
trial bo22334 (sabrina)

immunogenisitetsdata fra bo22334/sabrina og
immunogenicity data from bo22334/sabrina and

de totale responsrate punktestimatene i den samlede analysen av 410 pasienter fra fase i og fase ii i sabrina-studien er vist i tabell 2.
the overall response rate point estimates for the pooled analysis of 410 patients in sabrina stages 1 and 2 are shown in table 2.

i fase iii studien sabrina (bo22334) ble lokale hudreaksjoner rapportert hos opptil 20 % av pasientene som fikk mabthera subkutan formulering.
in the nhl phase 3 trial sabrina (bo22334), local cutaneous reactions were reported in up to 20% of patients receiving subcutaneous mabthera.

forekomsten av anti-rituksimab eller anti-rhuph20 antistoffer hadde ingen åpenbar påvirkning på sikkerhet eller effekt (sabrina).
there was no apparent impact of the presence of anti-rituximab or anti-rhuph20 antibodies on safety or efficacy (sabrina).

tre pasienter i mabthera subkutan formuleringsstudien sabrina (bo22334), fikk utilsiktet subkutan formulering administrert intravenøst opp til en maksimal dose på 2780 mg rituksimab, uten noen uheldig effekt.
three patients in the mabthera subcutaneous formulation trial sabrina (bo22334) were inadvertently administered subcutaneous formulation through the intravenous route up to a maximum rituximab dose of 2780 mg with no untoward effect.

i sabrina studien ble alvorlig administrasjonsrelaterte reaksjoner (grad ≥ 3) rapportert hos to pasienter (2 %) etter administrering av mabthera subkutan formulering.
in trial sabrina, severe administration-related reactions (grade≥3) were reported in two patients (2%) following administration of mabthera subcutaneous formulation .

i sabrina studien (bo22334) var forekomsten av behandlingsutløst/forhøyet anti-rituksimab antistoffer i den subkutane gruppen lav og tilsvarende den som ble observert i den intravenøse gruppen (henholdsvis 2 % vs.
in the sabrina trial (bo22334) the incidence of treatment-induced/enhanced anti-rituximab antibodies in the subcutaneous group was low and similar to that observed in the intravenous group (2% vs.